Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 10-11, 2009, Pages 1036-1044

  Bachet, J B ^a,b,c   Mitry, E ^a,b   Lievre A ^b   Lepere C ^b   Vaillant, J N ^b,d   Declety, G ^a,b   Parlier, H ^b   Emile, J F ^a,b   Julie C ^a,b   Rougier, P ^a,b,c  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c Adebiopharm   (France)

^d Porte de St Cloud Clinic   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEASIBILITY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUMOR GROWTH;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 70350425429     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.03.017     Document Type: Article

References (46)

1. th century. Ann Oncol 14 Suppl. 5 (2003) v128-v149
2. Carpelan-Holmstrom M., Nordling S., Pukkala E., Sankila R., Luttges J., Kloppel G., et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54 (2005) 385-387
3. Bouvier A.M., Remontet L., Jougla E., Launoy G., Grosclaude P., Buemi A., et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 28 (2004) 877-881
4. Glimelius B., Hoffman K., Sjoden P.O., Jacobsson G., Sellstrom H., Enander L.K., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 (1996) 593-600
5. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
6. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
7. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schuller J., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (2007) 2212-2217
8. Philip P.A., Benedetti J., Fenoglio-Preiser C., Zalupski M., Lenz H., Goldman B., et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study (abstract). Proc Am Soc Clin Oncol 25 (2007) A4509
9. Kindler H.L., Niedzwiecki D., Hollis D., Oraefo E., Schrag D., Hurwitz H., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) (abstract). Proc Am Soc Clin Oncol 25 (2007) A4508
10. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
11. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., and Benson III A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270-3275
12. Colucci G., Giuliani F., Gebbia V., Biglietto M., Rabitti P., Uomo G., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94 (2002) 902-910
13. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
14. Van Cutsem E., van d V., Karasek P., Oettle H., Vervenne W.L., Szawlowski A., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22 (2004) 1430-1438
15. Rocha Lima C.M., Green M.R., Rotche R., Miller Jr. W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
16. Oettle H., Richards D., Ramanathan R.K., van Laethem J.L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16 (2005) 1639-1645
17. Abou-Alfa G.K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N.S., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24 (2006) 4441-4447
18. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006) 3946-3952
19. Heinemann V., Labianca R., Hinke A., and Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18 (2007) 1652-1659
20. Banu E., Banu A., Fodor A., Landi B., Rougier P., Chatellier G., et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 24 (2007) 865-879
21. Ducreux M., Rougier P., Pignon J.P., Douillard J.Y., Seitz J.F., Bugat R., et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13 (2002) 1185-1191
22. Rougier P., Zarba J.J., Ducreux M., Basile M., Pignon J.P., Mahjoubi M., et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4 (1993) 333-336
23. Rothenberg M.L., Moore M.J., Cripps M.C., Andersen J.S., Portenoy R.K., Burris III H.A., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7 (1996) 347-353
24. Mitry E., Ducreux M., Ould-Kaci M., Boige V., Seitz J.F., Bugat R., et al. Oxaliplatin combined with 5-FU in second-line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 30 (2006) 357-363
25. Oettle H., Arnold D., Esser M., Huhn D., and Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11 (2000) 635-638
26. Kozuch P., Grossbard M.L., Barzdins A., Araneo M., Robin A., Frager D., et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6 (2001) 488-495
27. Ulrich-Pur H., Raderer M., Verena K.G., Schull B., Schmid K., Haider K., et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88 (2003) 1180-1184
28. Cantore M., Rabbi C., Fiorentini G., Oliani C., Zamagni D., Iacono C., et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67 (2004) 93-97
29. Milella M., Gelibter A., Di Cosimo S., Bria E., Ruggeri E.M., Carlini P., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 (2004) 133-138
30. Tsavaris N., Kosmas C., Skopelitis H., Gouveris P., Kopterides P., Loukeris D., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 23 (2005) 369-375
31. Reni M., Pasetto L., Aprile G., Cordio S., Bonetto E., Dell'Oro S., et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94 6 (2006) 785-791
32. Demols A., Peeters M., Polus M., Marechal R., Gay F., Monsaert E., et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94 (2006) 481-485
33. Ignatiadis M., Polyzos A., Stathopoulos G.P., Tselepatiotis E., Christophylakis C., Kalbakis K., et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71 (2006) 159-163
34. Xiong H.Q., Wolff R.A., Hess K.R., Varadhachary G.R., Blais J.C., et al. A phase II trial of oxaliplatin plus capecitabine (xelox) as second-line therapy for patients with advanced pancreatic cancer (abstract). Proc Am Soc Clin Oncol 24 (2006) A4119
35. Gebbia V., Maiello E., Giuliani F., Borsellino N., Caruso M., Di Maggio G., et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 18 Suppl. 6 (2007) vi124-vi127
36. Boeck S., Weigang-Kohler K., Fuchs M., Kettner E., Quietzsch D., Trojan J., et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18 (2007) 745-751
37. Riess H., Pelzer U., Stieler J., Schwaner I., Heil G., Görner M., et al. A randomized second-line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003 (abstract). Proc Am Soc Clin Oncol 25 (2007) A4517
38. Bachet J.B., Mitry E., Lepere C., Declety G., Vaillant J.N., Parlier H., et al. Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?. Gastroenterol Clin Biol 31 (2007) 151-156
39. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
40. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4 (1998) 1079-1086
41. Bonetti A., Zaninelli M., Leone R., Franceschi T., Fraccon A.P., Pasini F., et al. Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann Oncol 12 (2001) 187-191
42. Kaplan E.L., and Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 53 (1958) 457-481
43. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc B 34 (1972) 187-220
44. Mitry E., Dahan M., Ychou M., Arthaud J., Gasmi M., Raoul J., et al. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase II trial (FFCD 0301) (abstract). Proc Am Soc Clin Oncol 26 (2008) A4513
45. O'Reilly E.M., Niedzwiecki D., Hollis D.R., Bekaii-Saab T.S., Pluard T., Duffy A., et al. A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603 (abstract). Proc Am Soc Clin Oncol 26 (2008) A4515
46. Pelzer U., Kubica K., Stieler J., Schwaner I., Heil G., Görner M., et al. A randomized trial with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study (abstract). Proc Am Soc Clin Oncol 26 (2008) A4508